| Product Name | CGRP ELISA kit (Human) |
|---|---|
| Description | This assay has high sensitivity and excellent specificity for detection of Calcitonin Gene Related Peptide (CGRP). No significant cross-reactivity or interference between Calcitonin Gene Related Peptide (CGRP) and analogues was observed. |
| Synonyms | CALCB; CGRP2; CALC2; CGRP-II; Calcitonin Gene Related Peptide 2; Calcitonin 2; Calcitonin Related Polypeptide Beta |
| Method | Competitive |
| Detection Range | 6.17-500pg/mL |
| Sensitivity | 2.23pg/mL |
| Target | CGRP |
| Specificity | This assay has high sensitivity and excellent specificity for detection of Calcitonin Gene Related Peptide (CGRP). No significant cross-reactivity or interference between Calcitonin Gene Related Peptide (CGRP) and analogues was observed. |
| Reactivity | Human |
| Sample Types | Serum, Plasma, Tissue Homogenates, Cell Lysates, Cell Culture Supernates And Other Biological Fluids |
| Reconstitution | 1.Prepare all reagents, samples and standards; 2.Add 50uL standard or sample to each well. And then add 50uL prepared Detection Reagent A immediately. Shake and mix.Incubate 1 hour at 37℃; 3.Aspirate and wash 3 times; 4.Add 100uL prepared Detection Reagent B.Incubate 30 minutes at 37℃; 5.Aspirate and wash 5 times; 6.Add 90uL Substrate Solution.Incubate 10-20 minutes at 37℃; 7.Add 50uL Stop Solution.Read at 450 nm immediately. |
| Uniprot | P10092 |
| Storage | 4°C for 1 month/ -20°C for long-term(within shelf life) |
| Notes | Colormetric |
| References | Alstonia scholaris R. Br. Significantly Inhibits Retinoid-Induced Skin Irritation In Vitro and In Vivo.;Increased levels of CGRP in peripheral blood in women with chronic migraine: A reliable biological marker;CGRP and VIP Levels as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine;Prognostic significance of circulating and endothelial progenitor cell markers in type 2 diabetic foot.;Calcitonin gene-and parathyroid hormone-related peptides in normotensive and preeclamptic pregnancies: a nested case–control study;OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine;Effect of acupuncture on house dust mite specific IgE, substance P, and symptoms in persistent allergic rhinitis;Relationship between serum levels of VIP, but not of CGRP, and cranial autonomic parasympathetic symptoms: A study in chronic migraine patients;Transient Receptor Potential Vanilloid Subtype 1 Inhibits Inflammation and Apoptosis via the Release of Calcitonin Gene-Related Peptide in the Heart after Myocardial Infarction.;Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome;Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal;Periodontal inflammation is related to increased serum calcitonin gene‐related peptide (CGRP) levels in patients with chronic migraine;Electrical stimulation of the superior sagittal sinus suppresses A-type K currents and increases P/Q-and T-type Ca 2 currents in rat trigeminal ganglion …;Effects of endurance exercise on serum concentration of calcitonin gene-related peptide (CGRP): a potential link between exercise intensity and headache;Serum CGRP, VIP, and PACAP usefulness in migraine: a case–control study in chronic migraine patients in real clinical practice;Mild systemic inflammation enhances response to OnabotulinumtoxinA in chronic migraineurs;Perirenal adipose afferent nerves sustain pathological high blood pressure in rats; |
| Supplier | Cloud Clone |
PROTOCOLS:
CEA876Hu All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
